索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]李娜,王鹤儒,程义浩,等.生物可吸收支架的临床应用[J].国际心血管病杂志,2022,05:271-274.
点击复制

生物可吸收支架的临床应用(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年05期
页码:
271-274
栏目:
综述
出版日期:
2022-10-01

文章信息/Info

Title:
-
作者:
李娜; 王鹤儒; 程义浩; 赵雷
130041 长春，吉林大学第二医院心血管内科
Author(s):
-
关键词:
经皮冠状动脉介入术;  生物可吸收支架;  药物洗脱支架
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.05.005
文献标识码:
-
摘要:
生物可吸收支架在植入后可提供与其他类型支架类似的早期给药及血管支撑， 并且可在数年内完全降解吸收，恢复血管的结构和收缩、舒张功能，理论上可降低晚期不良 事件发生率。生物可吸收支架应用范围包括急性冠脉综合征、慢性完全性闭塞病变、冠状 动脉分叉病变等。
Abstract:
-

参考文献/References

[1] Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy[J]. Lancet, 2017, 390(196):760-772.
[2] Masiero G, Rodinò G, Boiago M, et al. Bioresorbable scaffolds in percutaneous coronary intervention: facing old problems, raising new hopes[J]. Curr Cardiol Rep, 2021, 23(3):15.
[3] Tenekecioglu E, Farooq V, Bourantas CV, et al. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention[J]. BMC Cardiovasc Disord, 2016, 16:38.
[4] Giacchi G, Ortega-Paz L, Brugaletta S, et al. Bioresorbable vascular scaffolds technology: current use and future developments[J]. Med Devices (Auckl), 2016, 9:185-198.
[5] Ke J, Zhang H, Huang J, et al. Mid-term outcomes of bioresorbable vascular scaffolds vs second-generation drugeluting stents in patients with acute coronary syndromes: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(10):e19458.
[6] Brugaletta S, Gori T, Tousek P, et al. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study[J]. EuroIntervention, 2020, 15(16):1436-1443.
[7] ?akal S, ?akal B, Karaca O, et al. Long-term outcomes of Absorb bioresorbable vascular scaffold using predilation, sizing, and postdilation protocol in a real-world patient population[J]. Turk Kardiyol Dern Ars, 2021, 49(1):40-50.
[8] Cayla G, Koning R, Fajadet J, et al. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the France ABSORB registry[J]. Arch Cardiovasc Dis, 2019, 112(2):113-123.
[9] Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan[J]. Eur Heart J, 2015, 36(47):3332-3342.
[10] Desperak P, Hawranek M, Chodór PA, et al. Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction[J]. Postepy Kardiol Interwencyjnej, 2020, 16(1):49-57.
[11] Ni L, Chen H, Luo Z, et al. Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis[J]. J Cardiothorac Surg, 2020, 15(1):26.
[12] Verdoia M, Kedhi E, Suryapranata H, et al. Poly (l-lactic acid) bioresorbable scaffolds versus metallic drug-eluting stents for the treatment of coronary artery disease: a meta-analysis of 11 randomized trials[J]. Catheter Cardiovasc Interv, 2020, 96(4):813-824.
[13] Lipinski MJ, Escarcega RO, Baker NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis[J]. JACC Cardiovasc Interv, 2016, 9(1):12- 24.
[14] Polimeni A, Anadol R, Münzel T, et al. Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs[J]. BMC Cardiovasc Disord, 2017, 17(1):147.
[15] Ali ZA, Gao R, Kimura T, et al. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data metaanalysis from the ABSORB randomized trials[J]. Circulation, 2018, 137(5):464-479.
[16] Kozuma K, Tanabe K, Hamazaki Y, et al. Long-term outcomes of absorb bioresorbable vascular scaffold vs. everolimuseluting metallic stent―a randomized comparison through 5 years in Japan[J]. Cir J, 2020, 84(5):733-741
[17] Brilakis ES, Mashayekhi K, Tsuchikane E, et al. Guiding principles for chronic total occlusion percutaneous coronary intervention[J]. Circulation, 2019, 140(5):420-433.
[18] Jones DA, Weerackody R, Rathod K, et al. Successful recanalization of chronic total occlusions is associated with improved long-term survival[J]. JACC Cardiovasc Interv, 2012, 5(4):380-388.
[19] Brilakis ES, Banerjee S, Karmpaliotis D, et al. Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a report from the NCDR (National Cardiovascular Data Registry)[J]. JACC Cardiovasc Interv, 2015, 8(2):245-253.
[20] De Felice F, Fiorilli R, Parma A, et al. 3-year clinical outcome of patients with chronic total occlusion treated with drugeluting stents[J]. JACC Cardiovasc Interv, 2009, 2(12):1260- 1265.
[21] Polimeni A, Anadol R, Münzel T, et al. Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: a meta-analysis[J]. BMC Cardiovasc Disord, 2019, 19(1):59.
[22] Marchenko R, Nazir S, Malla S, et al. Clinical outcomes of successful revascularization of chronic total coronary occlusions with bioresorbable vascular scaffolds: a systematic review[J]. Cureus, 2018, 10(11):e3647.
[23] La Manna A, Chisari A, Giacchi G, et al. Everolimus-eluting bioresorbable vascular scaffolds versus second Generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: technical and procedural outcomes from the GHOST-CTO registry[J]. Catheter Cardiovasc Interv, 2016, 88(6):E155-E163.
[24] Elwany M, Zaki A, Latib A, et al. The impact of the use of bioresorbable vascular scaffolds and drug-coated balloons in coronary bifurcation lesions[J]. Egypt Heart J, 2019, 71(1):31.
[25] Rampat R, Mayo T, Hildick-Smith D, et al. A randomized trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds—the Absorb Bifurcation Coronary (ABC) trial[J]. Cardiovasc Revasc Med, 2019, 20(1):43-49.
[26] ?anocha M, Lesiak M. Complete healing of a bifurcation lesion treated with the implantation of 2 bioresorbable vascular scaffolds with the T and small protrusion technique[J]. Kardiol Pol, 2019, 77(4):488-489.
[27] Elabbassi W, Chowdhury M, Hatala R. Use of bioresorbable vascular scaffold technology in treating coronary bifurcation lesions: a report about long-term clinical results and review of available literature[J]. Bratisl Lek Listy, 2019, 120(8):545- 551.
[28] Naganuma T, Kawamoto H, Panoulas VF, et al. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions[J]. Int J Cardiol, 2017, 246:26-31.

备注/Memo

备注/Memo:
通信作者：赵雷， E-mail：zhaolei0518@aliyun.com
更新日期/Last Update: 2022-10-01